PLAINSBORO, N.J., April 26, 2018 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will present at the following healthcare conferences in May:
- On Tuesday, May 15, 2018 at 10:40 a.m. PT, Glenn Coleman, chief financial officer and corporate vice president of International, will present at the Bank of America Merrill Lynch 2018 Healthcare Conference in Las Vegas, NV. The session will be available through live audio webcast and can be accessed from the Investor section of www.integralife.com.
- On Monday, May 21, 2018 at 11:30 a.m. ET, Sravan Emany, vice president, treasurer and investor relations, will present at the 2018 UBS Global Healthcare Conference in New York, NY.
About Integra LifeSciences
Integra LifeSciences is a global leader in regenerative technologies, neurosurgical and extremity orthopedic solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, Cadence®, CertasTM, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MediHoney®, MicroFrance®, PriMatrix®, Salto Talaris®, SurgiMend®, TCC-EZ®, Titan™ and VersaTru™. For the latest news and information about Integra and its brands, please visit www.integralife.com.
Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2017 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contacts:
Sravan Emany
Vice President, Treasury & Investor Relations
(609) 936-2488
[email protected]
Michael Beaulieu
Director, Investor Relations
(609) 750-2827
[email protected]
Media Contact:
Laurene Isip
Senior Director, Global Corporate Communications
(609) 750-7984
[email protected]


BHP Attracts AI-Focused Investors as Copper Demand Surges
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert
Continental AG Shares Jump After Q1 Profit Beats Expectations
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 



